Bharat Immunological & Biological Corporation Ltd (BIBCL) — shareholding pattern, promoter holding, financials and share price
About Bharat Immunological & Biological Corporation Ltd (BIBCL)
Bharat Immunological & Biological Corporation Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as BIBCL and on the BSE under scrip code 524663. Its ISIN is INE994B01014.
Incorporated in 1989, Bharat Immunological and Biologicals Corporation Ltd manufactures biotechnology-based pharmaceuticals. [1]
Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit specializing in vaccines and pharmaceutical products, under the Department of Biotechnology.
The company manufactures Oral Polio Vaccine (OPV), Zinc Tablets, and diarrhea management kits, and has diversified into plasma-derived medicines and oral cholera vaccine.
Listed peers in Pharmaceuticals: Vineet Laboratories Ltd, Onyx Biotec Ltd, Source Natural Foods & Herbal Supplements Ltd, Ajooni Biotech Ltd, Vilin Bio Med Ltd, Phaarmasia Ltd.
Valuation & Returns
28 Jul 2026At ₹15.82 a share on 28 Jul 2026, Bharat Immunological & Biological Corporation Ltd (BIBCL) was valued at a price-to-earnings ratio of -3.77x against an industry P/E of 37.21x and a price-to-book of 0.78x on a book value of ₹20.33 per share as of Mar 2023. Solomo computes return on equity of -20.58% and return on capital employed of -10.82% from filed results. Earnings ratios use standalone results for the twelve months Dec 2022 to Sep 2023.
- P/E
- -3.77x
- Industry P/E
- 37.21x
- P/B
- 0.78x
- EPS (TTM)
- ₹-4.18
- Book value / share
- ₹20.33
- ROE
- -20.58%
- ROCE
- -10.82%
- ROA
- -9.73%
- Debt / equity
- 0.8x
- Dividend yield
- 0%
- EBITDA margin
- -220.65%
- 52-week range
- ₹14.1 – ₹23.19
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2023In the year ended Mar 2023, Bharat Immunological & Biological Corporation Ltd (BIBCL) reported revenue of ₹45 crore, net profit of ₹-17 crore and earnings per share of ₹-3.95. That compares with revenue of ₹78 crore and net profit of ₹-9 crore in Mar 2022. Figures are standalone, as filed with the exchanges.
In the quarter ended Sep 2023, net profit ₹-4.92 crore (standalone).
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 84 | 67 | 85 | 78 | 45 |
| Net profit (₹ cr) | -6 | -10 | -18 | -9 | -17 |
| EPS (₹) | -1.34 | -2.36 | -4.19 | -2.03 | -3.95 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -15.49% | 5.09% | -12.61% | -43.09% |
| Profit growth | - | - | - | -94.97% |
Ownership Summary
Mar 2024As of Mar 2024, promoters hold 59.25% of Bharat Immunological & Biological Corporation Ltd (BIBCL) (unchanged from the previous quarter). Market capitalisation was ₹68 crore on 28 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2003.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2024 | 59.25% | - | - | - | 40.75% |
| Dec 2023 | 59.25% | - | - | - | 40.75% |
| Sep 2023 | 59.25% | - | - | - | 40.75% |
| Jun 2023 | 59.25% | - | - | - | 40.75% |
| Mar 2023 | 59.25% | - | - | - | 40.75% |
| Dec 2022 | 59.25% | - | - | - | 40.75% |
| Sep 2022 | 59.25% | - | - | - | 40.75% |
| Jun 2022 | 59.25% | - | 0% | 0% | 40.75% |